Similarly, patients receiving hormone ablation therapy for breast cancer (estrogen suppression) or prostate cancer (chemical or surgical castration for testosterone suppression) may also suffer osteoporotic bone loss due to increased RANKL expression (112, 113). The gene discussed is TNFSF11; the disease is prostate carcinoma.